Navigation Links
Co-Promotion of a New Medical Device for Female Infertility Announced
Date:1/18/2011

SPARTANBURG, S.C., Jan. 18, 2011 /PRNewswire/ -- Norgenix Pharmaceuticals, LLC (www.norgenixpharma.com), a wholly owned subsidiary of Spartanburg-based J M Smith Corporation, and Fertility Focus Limited (www.fertility-focus.com) today announced a partnership for the co-promotion of the Fertiloscope, a CE marked and 510(k) approved surgical instrument for the early diagnosis and immediate corrective surgery of physical causes of female infertility. Norgenix has exclusive rights to market and distribute the Fertiloscope in the United States, as well as US territories and military bases. The product will benefit from the strategic support of Glenveigh Medical (www.glenveigh.com) as well, with whom Norgenix has an existing alliance in the U.S. to promote medical devices developed by Glenveigh.

Norgenix and Fertility Focus also announced a strategic alliance and revealed its first medical device co-promotion, the Fertiloscope. Norgenix is a North American specialty pharmaceutical, medical device and biotechnology company that engages in the development, commercialization, and sales of products in the women's health arena. Norgenix is licensed to sell, market, and distribute prescription drug products and medical devices in all 50 U.S. states. Fertility Focus is a United Kingdom based company that develops devices aimed at the infertility market.

Developed by the eminent French surgeon Dr. Antoine Watrelot, the Fertiloscope, is a novel laparoscope for minimally invasive trans-vaginal use in a procedure that is known as Fertiloscopy. The Fertiloscopeis the only method of primary screening that provides gold standard accuracy in a day-case or office setting. This relatively new surgical technique is used for the early diagnosis and immediate treatment of a number of disorders of the female reproductive organs.

Norgenix is dedicated to in-licensing product opportunities and building strategic alliances with companies interested in maximizing the value of products that fulfill unmet medical needs in the U.S. marketplace. As a strategic partner, Norgenix and the related J M Smith partner companies will provide strategic direction and capitalization to build success.MEDIA CONTACT:  Sims Hammond 864.580.2350 Sims@LaunchSomething.com
'/>"/>

SOURCE Norgenix Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
2. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
3. Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
4. Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
5. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
8. Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011
9. Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010
10. Mindray Medical to Exhibit at Arab Health 2011 in Dubai from January 24-27
11. Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwCs Medical Technology Innovation Scorecard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):